Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology · Phase I

Oncology programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs 1,319

Quick answer

Oncology Phase I programs: NovaPharmaNews indexes 1,319 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Pipeline programs

Page 8 of 28

  1. CA111-001

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Malignant Tumors

    phase 1 other active

    1 trial

  2. CA127-1027

    Bristol-Myers Squibb Australia Pty Ltd

    Non-small Cell Lung Cancer (NSCLC)

    phase 1 other active

    1 trial

  3. CA177-1036

    Turn Therapeutics

    Phase 1: Advanced solid tumors harboring genetic alterations in MET

    phase 1 other active

    1 trial

  4. CA235-0001

    Bristol-Myers Squibb Australia Pty Ltd

    Acute Myeloid Leukemia and Myelodysplastic Syndrome

    phase 1 other active

    1 trial

  5. CA240-0008

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  6. CA243-0001

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced or metastatic solid tumors, Gastroesophageal cancer (GEC), High grade serous ovarian cancer (HGSOC), Endometrial cancer (EC), Advanced or metastatic breast cancer, Platinum-resistant ovarian cancer (PROC)

    phase 1 other active

    1 trial

  7. CAAA617A12101

    Novartis Pharmaceuticals

    Metastatic Castration-Resistant Prostate Cancer

    phase 1 small molecule active

    1 trial

  8. CADPT01C12101

    Novartis Pharmaceuticals

    Advanced or metastatic BRAF V600 colorectal cancer.

    phase 1 other active

    1 trial

  9. CAN-2409 + valacyclovir

    Candel Therapeutics

    Lung Cancer

    phase 1 mab completed

    1 trial

  10. CAR T cells

    Qian Wenbin

    B-Cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  11. CAR T cells chimeric antigenreceptor cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  12. CAR T-cell therapy

    Hospital Authority, Hong Kong

    Lymphoblastic Leukemia, Acute, Childhood

    phase 1 mab active

    1 trial

  13. CAR-T Therapy

    Zhao Weili

    Peripheral T Cell Lymphoma

    phase 1 small molecule active

    1 trial

  14. CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Relapsed Non-Hodgkin Lymphoma

    phase 1 mab active

    1 trial

  15. CAR-T cells Infusion chimeric antigen receptor T cells

    The First People's Hospital of Lianyungang

    Relapsed/Refractory Plasma Cell Leukemia

    phase 1 small molecule active

    1 trial

  16. CAR-T cells chimenric antigen receptor T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-Cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  17. CAR-T cells chimeric antigen receptor T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory Acute Myeloid Leukemia(AML)

    phase 1 small molecule active

    1 trial

  18. CAR123 T cell treatment of relapsed/refractory hematologic malignancies.

    The George Institute

    Relapsed/refractory CD123+ hematological malignancies: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Lymphoblastic Leukemia.

    phase 1 other active

    1 trial

  19. CART19 cell and auto-HSCT

    Shenzhen Second People's Hospital

    Leukemia, Lymphocytic, Acute, B-Cell

    phase 1 mab active

    1 trial

  20. CARTmeso CART19

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    phase 1 mab active

    1 trial

  21. CB-010

    Caribou Biosciences

    Lymphoma, Non-Hodgkin

    phase 1 gene therapy active

    1 trial

  22. CB-012

    Caribou Biosciences

    Acute Myeloid Leukemia, in Relapse

    phase 1 small molecule terminated

    1 trial

  23. CBG131 CAR-T Cell Infusion

    The First People's Hospital of Lianyungang

    Advanced Gastric and Pancreatic Cancer

    phase 1 small molecule active

    1 trial

  24. CC-122

    Bristol-Myers Squibb

    Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  25. CC-486

    Celgene Europe Limited

    Leukemia, Myeloid, Acute

    phase 1 small molecule completed

    1 trial

  26. CC-90010-GBM-002

    Celgene Europe Limited

    Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who have undergone complete or partial tumor resection

    phase 1 other active

    1 trial

  27. CC-90010-ST-001

    Celgene Europe Limited

    Part C: advanced or unresectable STs (Spain only), Part B : r/r diffuse large B cell lymphoma (DLBCL) (Cohort 1), advanced basal cell carcinoma (BCC) (Cohort 2), r/r DLBCL under an alternative dosing regimen (Cohort 3), Part A: advanced or unresectable solid tumors (STs) and relapsed and/or refractory (r/r) advanced non-Hodgkin's lymphomas (NHLs)

    phase 1 other active

    1 trial

  28. CC-90011-SCLC-001

    Celgene Europe Limited

    extensive stage small cell lung cancer

    phase 1 other active

    1 trial

  29. CCT3833

    United Therapeutics Europe Ltd

    Melanoma

    phase 1 small molecule completed

    1 trial

  30. CD-001

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Malignant Neoplasm

    phase 1 small molecule active

    1 trial

  31. CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine

    United Therapeutics Europe Ltd

    HER2 Negative Breast Carcinoma

    phase 1 mab active

    1 trial

  32. CD19-CD22 CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

    phase 1 mab terminated

    1 trial

  33. CD19-TriCAR-T/SILK

    Biotech Pharmaceutical Co.,

    Non-Hodgkin Lymphoma

    phase 1 mab active

    1 trial

  34. CD19/CD20 Dual-CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Non-Hodgkin's Lymphoma

    phase 1 mab on hold

    1 trial

  35. CD19/CD20 Dual-CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Leukemia

    phase 1 mab completed

    1 trial

  36. CD7 UCAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    T-cell Leukemia

    phase 1 mab active

    1 trial

  37. CD70 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Metastatic Tumor

    phase 1 mab active

    4 trials

  38. CD70 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Renal Cell Carcinoma

    phase 1 mab active

    1 trial

  39. CD70 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Ovarian Cancer

    phase 1 mab active

    1 trial

  40. CD70-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Renal Cell Carcinoma (RCC)

    phase 1 mab active

    1 trial

  41. CDFF332A12101

    Novartis Pharmaceuticals

    Advanced, relapsed Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  42. CDKY709A12101C

    Novartis Pharmaceuticals

    Nasopharyngeal Carcinoma, Triple Negative Breast Cancer, Microsatellite Stable Colorectal Cancer, Non-Small Cell Lung Cancer, Cutaneous Melanoma

    phase 1 other active

    1 trial

  43. CEA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Colorectal Cancer

    phase 1 mab active

    1 trial

  44. CEA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Gastric Cancer

    phase 1 mab active

    1 trial

  45. CEA protein antigen plus BCG Vaccine Mix for percutaneous use

    Lxo Ireland Designated Activity Company

    Rectal Cancer

    phase 1 mab active

    1 trial

  46. CEA-targeted CAR-T (Intravenous)

    Chongqing Precision Biotech Co., Ltd

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 1 mab active

    1 trial

  47. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Colorectal Cancer

    phase 1 mab active

    1 trial

  48. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Peritoneal Metastases From Colorectal Cancer

    phase 1 mab active

    1 trial

Frequently asked questions

How many oncology Phase I programs exist?

1,319 programs match both the therapeutic area and stage filters in our published index.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.